GlaxoSmithKline to commercialise Cann Group cannabis medication

Medicinal cannabis producer Cann Group and global pharmaceutical firm GlaxoSmithKline are progressing negotiations relating to the commercialisation of Cann’s Satipharm CBD capsules. Cann Group, which operates a major cannabis growing and processing centre at Mildura, Victoria (pictured) announced it was in negotiation with GlaxoSmithKline’s Australian arm Haleon. The negotiations involve an exclusive agreement covering distribution…

Calix awarded $947,000 for engineering and design study on demo-scale iron factory

The Australian Renewable Energy Agency has announced $947,000 in funding to Calix, supporting an investigation into the feasibility of a hydrogen direct reduced iron (DRI) plant using the Australian company’s Zero Emissions Steel Technology (ZESTY) process. According to a statement from ARENA, the funding would assist a pre-FEED and FEED (Front End Engineering and Design)…